StockData
Bioxytran, Inc logo

Bioxytran, Inc (BIXT) stock

BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30
$0.02−0.00 (-3.95%)

Close on Oct 19, 2026Market cap $2.56MP/E –Yield –

Bioxytran revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Bioxytran's revenue for the twelve months ending Jun 30, 2018 was $177.80K, down 13.8% year over year. For fiscal 2017 it was $191.08K, down 22.5% from the year before. The highest annual figure on record is $417.34K in fiscal 2013.

Annual revenue

PeriodPeriod endValueChange
FY2017Dec 31, 2017$191.08K-22.5%
FY2016Dec 31, 2016$246.50K-3.6%
FY2015Dec 31, 2015$255.82K-7.2%
FY2014Dec 31, 2014$275.62K-34.0%
FY2013Dec 31, 2013$417.34K+33.4%
FY2012Dec 31, 2012$312.90K+310.1%
FY2011Dec 31, 2011$76.30K+372.9%
FY2010Dec 31, 2010$16.13K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2018Jun 30, 2018$20.31K-48.5%
Q1 FY2018Mar 31, 2018$13.32K+79.1%
Q4 FY2017Dec 31, 2017$32.19K-44.7%
Q3 FY2017Sep 30, 2017$111.98K+10.7%
Q2 FY2017Jun 30, 2017$39.47K–
Q1 FY2017Mar 31, 2017$7.44K–
Q4 FY2016Dec 31, 2016$58.20K–
Q3 FY2016Sep 30, 2016$101.14K–

More Bioxytran figures

See a number that looks wrong?